In last trading session, Vera Therapeutics Inc. (NASDAQ:VERA) saw 3.32 million shares changing hands with its beta currently measuring 0.36. Company’s recent per share price level of $17.09 trading at $0.54 or 3.26% at ring of the bell on the day assigns it a market valuation of $761.53M. That closing price of VERA’s stock is at a discount of -36.86% from its 52-week high price of $23.39 and is indicating a premium of 69.57% from its 52-week low price of $5.20. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.79 million shares which gives us an average trading volume of 593.97K if we extend that period to 3-months.
For Vera Therapeutics Inc. (VERA), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.10. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.55 in the current quarter.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
Vera Therapeutics Inc. (NASDAQ:VERA) trade information
Upright in the green during last session for gaining 3.26%, in the last five days VERA remained trading in the red while hitting it’s week-highest on Tuesday, 09/12/23 when the stock touched $17.09 price level, adding 12.0% to its value on the day. Vera Therapeutics Inc.’s shares saw a change of -11.68% in year-to-date performance and have moved -7.52% in past 5-day. Vera Therapeutics Inc. (NASDAQ:VERA) showed a performance of -0.64% in past 30-days. Number of shares sold short was 3.27 million shares which calculate 8.12 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $21.67 to the stock, which implies a rise of 21.14% to its current value. Analysts have been projecting $16.00 as a low price target for the stock while placing it at a high target of $27.00. It follows that stock’s current price would drop -57.99% in reaching the projected high whereas dropping to the targeted low would mean a gain of 6.38% for stock’s current value.
Vera Therapeutics Inc. (VERA) estimates and forecasts
Statistics highlight that Vera Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added 135.40% of value to its shares in past 6 months, showing an annual growth rate of 25.67% while that of industry is 12.00. Apart from that, the company came raising its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to increase by 39.60% in the current quarter and calculating 50.80% increase in the next quarter.
VERA Dividends
Vera Therapeutics Inc. is more likely to be releasing its next quarterly report between November 08 and November 12 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Vera Therapeutics Inc. (NASDAQ:VERA)’s Major holders
Insiders are in possession of 7.35% of company’s total shares while institution are holding 97.09 percent of that, with stock having share float percentage of 104.79%. Investors also watch the number of corporate investors in a company very closely, which is 97.09% institutions for Vera Therapeutics Inc. that are currently holding shares of the company. FMR, LLC is the top institutional holder at VERA for having 6.54 million shares of worth $111.69 million. And as of Jun 29, 2023, it was holding 14.75% of the company’s outstanding shares.
The second largest institutional holder is Commodore Capital Lp, which was holding about 5.45 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 12.30% of outstanding shares, having a total worth of $93.14 million.
On the other hand, Fidelity Series Small Cap Opportunities Fund and Fidelity Select Portfolios – Health Care are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 1.05 million shares of worth $18.01 million or 2.38% of the total outstanding shares. The later fund manager was in possession of 1.0 million shares on Jul 30, 2023, making its stake of worth around $17.09 million in the company or a holder of 2.26% of company’s stock.
- Tags: NASDAQ:VERA, VERA, VERA stock, Vera Therapeutics Inc.
